[1] |
中华医学会结核病学分会结核性脑膜炎专业委员会. 2019中国中枢神经系统结核病诊疗指南. 中华传染病杂志, 2020, 38(7):400-408. doi:10.3760/cma.j.cn311365-20200606-00645.
|
[2] |
Davis A, Meintjes G, Wilkinson RJ. Treatment of Tuberculous Meningitis and Its Complications in Adults. Curr Treat Options Neurol, 2018, 20(3):5. doi:10.1007/s11940-018-0490-9.
|
[3] |
Armange L, Lacroix A, Petitgas P, et al. The use of TNF-α antagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: a case series and literature review. Eur J Clin Microbiol Infect Dis, 2023, 42(4):413-422. doi:10.1007/s10096-023-04564-2.
|
[4] |
Davis AG, Donovan J, Bremer M, et al. Host Directed Therapies for Tuberculous Meningitis. Wellcome Open Res, 2021, 5:292. doi:10.12688/wellcomeope nres.16474.2.
|
[5] |
Vargesson N, Stephens T. Thalidomide: history, withdrawal, renaissance, and safety concerns. Expert Opin Drug Saf, 2021, 20(12):1455-1457. doi:10.1080/14740338.2021.1991307.
pmid: 34623196
|
[6] |
Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci, 2020, 96(6):189-203. doi:10.2183/pjab.96.016.
|
[7] |
Van Toorn R, Solomons RS, Seddon JA, et al. Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort. Clin Infect Dis, 2021, 72(5):e136-e145. doi:10.1093/cid/ciaa1826.
|
[8] |
Kumar R, Kolloli A, Singh P, et al. Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model. Front Cell Infect Microbiol, 2020, 9:450. doi:10.3389/fcimb.2019.00450.
|
[9] |
Sarfaraz S, Iftikhar S, Salahuddin N. Frequency, clinical characteristics, risks, and outcomes of Paradoxical upgrading reactions during anti-tuberculosis treatment in tuberculous lymphadenitis. Pak J Med Sci, 2020, 36(1):S27-S32. doi:10.12669/pjms.36.ICON-Suppl.1711.
|
[10] |
Santin M, Escrich C, Majòs C, et al. Tumor necrosis factor antagonists for paradoxical inflammatory reactions in the central nervous system tuberculosis: Case report and review. Medicine (Baltimore), 2020, 99(43):e22626. doi:10.1097/MD.0000000000022626.
|
[11] |
Van Toorn R, Zaharie SD, Seddon JA, et al. The use of thalidomide to treat children with tuberculosis meningitis: A review. Tuberculosis (Edinb), 2021, 130:102125. doi:10.1016/j.tube.2021.102125.
|
[12] |
Kwon JS, Park JH, Kim JY, et al. Diagnostic Usefulness of Cytokine and Chemokine Levels in the Cerebrospinal Fluid of Patients with Suspected Tuberculous Meningitis. Am J Trop Med Hyg, 2019, 101(2):343-349. doi:10.4269/ajtmh.18-0947.
|
[13] |
Liu P, Pei N, Liu X, et al. Thalidomide in the treatment of human immunodeficiency virus-negative tuberculous meningitis: A case report. Medicine (Baltimore), 2020, 99(40):e22639. doi:10.1097/MD.00000000000226 39.
|
[14] |
Panda PK, Panda P, Dawman L, et al. Efficacy and Safety of Thalidomide in Patients with Complicated Central Nervous System Tuberculosis: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg, 2021, 105(4):1024-1030. doi:10.4269/ajtmh.21-0108.
|